NO20064820L - Tetrahydrokarbazoler og derivater - Google Patents

Tetrahydrokarbazoler og derivater

Info

Publication number: NO20064820L
Authority: NO; Norway
Prior art keywords: diseases; alzheimer; disease; compounds; pharmaceutically acceptable
Prior art date: 2004-03-26

Application number

NO20064820A

Other languages

English (en)

Norwegian (no)

Inventor

Henrietta Dehmlow

Raffaello Masciadri

Bernd Kuhn

Matthew Blake Wright

Narendra Panday

Hasane Ratni

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-26

Filing date

2006-10-24

Publication date

2006-10-24

2006-10-24 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2006-10-24 Publication of NO20064820L publication Critical patent/NO20064820L/no

Links

XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical class N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 title 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
208000024827 Alzheimer disease Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102000004311 liver X receptors Human genes 0.000 abstract 2
108090000865 liver X receptors Proteins 0.000 abstract 2
206010008635 Cholestasis Diseases 0.000 abstract 1
208000032928 Dyslipidaemia Diseases 0.000 abstract 1
206010016654 Fibrosis Diseases 0.000 abstract 1
238000008214 LDL Cholesterol Methods 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
206010033645 Pancreatitis Diseases 0.000 abstract 1
206010040047 Sepsis Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
230000001668 ameliorated effect Effects 0.000 abstract 1
230000003143 atherosclerotic effect Effects 0.000 abstract 1
230000007870 cholestasis Effects 0.000 abstract 1
231100000359 cholestasis Toxicity 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
230000003920 cognitive function Effects 0.000 abstract 1
206010009887 colitis Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
230000004761 fibrosis Effects 0.000 abstract 1
230000001771 impaired effect Effects 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
150000002632 lipids Chemical class 0.000 abstract 1
210000004185 liver Anatomy 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20064820A 2004-03-26 2006-10-24 Tetrahydrokarbazoler og derivater NO20064820L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04101252		2004-03-26
PCT/EP2005/002869 WO2005092856A1 (en)	2004-03-26	2005-03-17	Tetrahydrocarbazoles and derivatives

Publications (1)

Publication Number	Publication Date
NO20064820L true NO20064820L (no)	2006-10-24

Family

ID=34963176

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20064820A NO20064820L (no)	2004-03-26	2006-10-24	Tetrahydrokarbazoler og derivater

Country Status (26)

Country	Link
US (2)	US20050215577A1 (de)
EP (1)	EP1732892B1 (de)
JP (1)	JP4705630B2 (de)
KR (1)	KR100803478B1 (de)
CN (1)	CN1938273B (de)
AR (1)	AR048334A1 (de)
AT (1)	ATE408599T1 (de)
AU (1)	AU2005225524B2 (de)
BR (1)	BRPI0509275A (de)
CA (1)	CA2560700A1 (de)
DE (1)	DE602005009811D1 (de)
DK (1)	DK1732892T3 (de)
ES (1)	ES2314633T3 (de)
HR (1)	HRP20080651T3 (de)
IL (1)	IL177704A (de)
MX (1)	MXPA06010815A (de)
MY (1)	MY140874A (de)
NO (1)	NO20064820L (de)
NZ (1)	NZ549396A (de)
PL (1)	PL1732892T3 (de)
PT (1)	PT1732892E (de)
RU (1)	RU2382770C2 (de)
SI (1)	SI1732892T1 (de)
TW (1)	TW200539870A (de)
WO (1)	WO2005092856A1 (de)
ZA (1)	ZA200607491B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20090086084A (ko)	2006-11-30	2009-08-10	코와 가부시키가이샤	치환 카르비놀 화합물
FR2913886B1 (fr)	2007-03-22	2012-03-02	Guerbet Sa	Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
US7919509B2 (en) *	2008-02-29	2011-04-05	Kowa Company, Ltd.	2-oxochromene derivatives
WO2009115212A1 (en) *	2008-03-17	2009-09-24	F. Hoffmann-La Roche Ag	Lxr ligand binding domain (lxr lbd) crystals
US7951822B2 (en) *	2008-03-31	2011-05-31	Kowa Company, Ltd.	1,3-dihydroisobenzofuran derivatives
JP5371118B2 (ja) *	2008-04-30	2013-12-18	興和株式会社	キノリン化合物
AU2009252615B2 (en) *	2008-05-29	2013-08-15	Kowa Company, Ltd.	Substituted carbinol compound having cyclic linker
FR2938537B1 (fr)	2008-11-14	2012-10-26	Sanofi Aventis	Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
KR101671046B1 (ko) *	2009-04-29	2016-10-31	코와 가부시키가이샤	헤테로환 링커를 갖는 카르비놀 화합물
PL2623499T3 (pl)	2010-10-01	2015-09-30	Taisho Pharmaceutical Co Ltd	Pochodne 1,2,4-triazolonu
DE102011055815A1 (de)	2011-11-29	2013-05-29	Aicuris Gmbh & Co. Kg	Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
CN107674071B (zh) *	2012-05-11	2021-12-31	同步制药公司	作为隐花色素调节剂的含有咔唑的磺酰胺类
DE102012016908A1 (de)	2012-08-17	2014-02-20	Aicuris Gmbh & Co. Kg	Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
WO2014145873A2 (en)	2013-03-15	2014-09-18	Epigen Biosciences, Inc.	Heterocyclic compounds useful in the treatment of disease
CN103910659B (zh) *	2013-11-04	2016-05-11	迈克斯(如东)化工有限公司	2-硝基-4-甲磺酰基苯甲酸的精制方法及其中间体
WO2015086642A1 (en)	2013-12-13	2015-06-18	F. Hoffmann-La Roche Ag	Inhibitors of bruton's tyrosine kinase
WO2015106164A1 (en)	2014-01-10	2015-07-16	Rgenix, Inc.	Lxr agonists and uses thereof
TWI690521B (zh)	2014-04-07	2020-04-11	美商同步製藥公司	作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
US10173978B2 (en)	2015-08-05	2019-01-08	Georgetown University	Small molecule androgen receptor inhibitors and methods of use thereof
EP3402477A4 (de)	2016-01-11	2019-08-21	The Rockefeller University	Verfahren zur behandlung von erkrankungen im zusammenhang mit aus myeloid abgeleiteten suppressorzellen
CA3078981A1 (en)	2017-11-21	2019-05-31	Rgenix, Inc.	Polymorphs and uses thereof
US20200085810A1 (en)	2018-07-26	2020-03-19	Hoffmann-La Roche Inc.	Compounds for use in treating kidney disorders
TWI888447B (zh)	2019-12-13	2025-07-01	美商因思博納公司	金屬鹽及其用途
CN111518002B (zh) *	2020-05-21	2022-06-21	南京林业大学	一种硫醚类化合物及其制备方法、医药中间体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003051837A2 (de) *	2001-12-14	2003-06-26	Zentaris Gmbh	Tetrahydrocarbazolderivate als liganden für g-protein gekoppelte rezeptoren (gpcr)
WO2003090746A1 (en) *	2002-04-23	2003-11-06	Chugai Seiyaku Kabushiki Kaisha	1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
WO2003090732A1 (en) *	2002-04-23	2003-11-06	Chugai Seiyaku Kabushiki Kaisha	Lxr modulators for the treatment of cardiovascular diseases
TWI329111B (en) *	2002-05-24	2010-08-21	X Ceptor Therapeutics Inc	Azepinoindole and pyridoindole derivatives as pharmaceutical agents
MXPA04011690A (es) *	2002-05-24	2005-03-31	Pharmacia Corp	Moduladores de receptor x de higado de sulfona.
US7125865B2 (en) *	2002-07-25	2006-10-24	Merck & Co., Inc.	Therapeutic compounds for treating dyslipidemic conditions

2005
- 2005-03-17 ES ES05716171T patent/ES2314633T3/es not_active Expired - Lifetime
- 2005-03-17 WO PCT/EP2005/002869 patent/WO2005092856A1/en not_active Ceased
- 2005-03-17 SI SI200530469T patent/SI1732892T1/sl unknown
- 2005-03-17 JP JP2007504315A patent/JP4705630B2/ja not_active Expired - Fee Related
- 2005-03-17 CN CN200580009767XA patent/CN1938273B/zh not_active Expired - Fee Related
- 2005-03-17 HR HR20080651T patent/HRP20080651T3/xx unknown
- 2005-03-17 EP EP05716171A patent/EP1732892B1/de not_active Expired - Lifetime
- 2005-03-17 KR KR1020067019738A patent/KR100803478B1/ko not_active Expired - Fee Related
- 2005-03-17 RU RU2006137655/04A patent/RU2382770C2/ru not_active IP Right Cessation
- 2005-03-17 CA CA002560700A patent/CA2560700A1/en not_active Abandoned
- 2005-03-17 AT AT05716171T patent/ATE408599T1/de active
- 2005-03-17 PT PT05716171T patent/PT1732892E/pt unknown
- 2005-03-17 DE DE602005009811T patent/DE602005009811D1/de not_active Expired - Lifetime
- 2005-03-17 BR BRPI0509275-2A patent/BRPI0509275A/pt not_active IP Right Cessation
- 2005-03-17 NZ NZ549396A patent/NZ549396A/en not_active IP Right Cessation
- 2005-03-17 DK DK05716171T patent/DK1732892T3/da active
- 2005-03-17 MX MXPA06010815A patent/MXPA06010815A/es active IP Right Grant
- 2005-03-17 PL PL05716171T patent/PL1732892T3/pl unknown
- 2005-03-17 AU AU2005225524A patent/AU2005225524B2/en not_active Ceased
- 2005-03-22 TW TW094108789A patent/TW200539870A/zh unknown
- 2005-03-23 US US11/088,065 patent/US20050215577A1/en not_active Abandoned
- 2005-03-23 AR ARP050101164A patent/AR048334A1/es active IP Right Grant
- 2005-03-24 MY MYPI20051291A patent/MY140874A/en unknown
2006
- 2006-08-24 IL IL177704A patent/IL177704A/en not_active IP Right Cessation
- 2006-09-07 ZA ZA200607491A patent/ZA200607491B/en unknown
- 2006-10-24 NO NO20064820A patent/NO20064820L/no not_active Application Discontinuation
2010
- 2010-05-06 US US12/774,779 patent/US7906546B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1732892A1 (de)	2006-12-20
AU2005225524A1 (en)	2005-10-06
ZA200607491B (en)	2008-06-25
ES2314633T3 (es)	2009-03-16
RU2006137655A (ru)	2008-05-10
CN1938273A (zh)	2007-03-28
JP4705630B2 (ja)	2011-06-22
US20100216833A1 (en)	2010-08-26
AR048334A1 (es)	2006-04-19
HK1101911A1 (en)	2007-11-02
CN1938273B (zh)	2011-12-14
ATE408599T1 (de)	2008-10-15
MXPA06010815A (es)	2006-12-15
RU2382770C2 (ru)	2010-02-27
NZ549396A (en)	2010-04-30
IL177704A0 (en)	2006-12-31
WO2005092856A8 (en)	2006-12-21
US7906546B2 (en)	2011-03-15
PL1732892T3 (pl)	2009-03-31
DK1732892T3 (da)	2009-01-05
TW200539870A (en)	2005-12-16
MY140874A (en)	2010-01-29
DE602005009811D1 (de)	2008-10-30
HRP20080651T3 (hr)	2009-01-31
US20050215577A1 (en)	2005-09-29
EP1732892B1 (de)	2008-09-17
IL177704A (en)	2011-09-27
AU2005225524B2 (en)	2007-11-22
SI1732892T1 (sl)	2009-02-28
BRPI0509275A (pt)	2007-09-04
PT1732892E (pt)	2008-12-22
CA2560700A1 (en)	2005-10-06
JP2007530480A (ja)	2007-11-01
KR20060124780A (ko)	2006-12-05
KR100803478B1 (ko)	2008-02-14
WO2005092856A1 (en)	2005-10-06

Legal Events

Date	Code	Title	Description
2013-10-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20064820L (no)	2006-10-24	Tetrahydrokarbazoler og derivater
AU2022201816A8 (en)	2022-04-21	Pyrrolopyrimidines as CFTR potentiators
NO20085060L (no)	2008-12-03	Triazolpyrazinderivater anvendelige som anti-cancermidler
WO2007107470A3 (en)	2007-11-08	Pyrazoles as 11-beta-hsd-1
EA200970090A1 (ru)	2009-06-30	Модуляторы метаболизма и лечение связанных с ним расстройств
NO20064456L (no)	2006-10-02	Thiadiazolidinoner som GSK-3 inhibitorer
NO20083642L (no)	2008-09-29	Dibenzylaminderivater som CETP-inhibitorer
WO2007082808A3 (en)	2007-09-13	Thiazoles as 11 beta-hsd1 inhibitors
WO2007060140A3 (en)	2007-09-13	Inhibitors of diacyglycerol acyltransferase (dgat)
EA200701746A1 (ru)	2007-12-28	Фармацевтические композиции для лечения или профилактики заболеваний, в том числе ожирения, диабета, метаболического синдрома, нейродегенеративных заболеваний и заболеваний, связанных с нарушением деятельности митохондрий
WO2008005534A3 (en)	2008-03-06	Orally dissolving formulations of memantine
WO2008033460A3 (en)	2009-02-12	Treating pain, diabetes, and lipid metabolism disorders
ATE429430T1 (de)	2009-05-15	Stoffwechselmodulatoren und behandlung damit verbundener erkrankungen
EA200970088A1 (ru)	2009-06-30	Модуляторы метаболизма и лечение связанных с ним нарушений
WO2003066629A3 (en)	2003-10-30	Heteroaryl compounds useful as inhibitors of gsk-3
NO20074872L (no)	2007-10-30	Pyrazoler
NO20080865L (no)	2008-04-18	Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
EA200801417A1 (ru)	2009-02-27	Соединение бициклического циннамида
WO2009010416A3 (en)	2009-03-05	Inhibitors of 11b-hydroxysteroid dehydrogenase
IL187005A0 (en)	2008-02-09	Diacylglycerol acyltransferase inhibitors
NO20072389L (no)	2007-08-23	Substituerte benzokinolizinderivater
NO20056010L (no)	2006-01-20	Biaryloksymetylaren-karboksylsyrer
MX2010009922A (es)	2010-09-28	Activadores de piridazinona glucocinasa.
EA200971050A1 (ru)	2010-06-30	Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
NO20076357L (no)	2008-03-14	Azabicykliske heterocykler som cannabinoid reseptor modulatorer